Home › NDC Lookup › RxCUI directory › RxCUI 2680309

1 ML iloprost 0.1 MG/ML Injection [Aurlumyn] — RxCUI 2680309

RxNorm drug concept · Semantic branded drug
RxCUI 2680309 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2680309
Official name1 ML iloprost 0.1 MG/ML Injection [Aurlumyn]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as1 ML Aurlumyn 0.1 MG/ML Injection; Aurlumyn 100 MCG in 1 ML Injection; Aurlumyn 100 MCG per 1 ML Injection
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Iloprost: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Aurlumyn is the brand name for iloprost given by IV infusion. It's approved to treat severe frostbite in adults — specifically to lower the chance that you'll lose a finger or toe...
  • No, you won't take this at home. Aurlumyn is given through an IV drip in a clinical setting — a hospital or infusion center — where your nurses and doctors can keep a close eye on...
  • How is this medication given? Do I take it at home?
  • The most common things people notice are headache, flushing (feeling warm or flushed in the face), a fast heartbeat, nausea, vomiting, and dizziness. These can feel uncomfortable b...
📖 Read our full Iloprost guide →

🕸️ Concept Web — How 1 ML iloprost 0.1 MG/ML Injection [Aurlumyn] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 1 ML iloprost 0.1 MG/ML Injection [Aurlumyn] RxCUI 2680309

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Iloprost 40138
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Aurlumyn 2680305
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Iloprost Injection 2680302
    • Iloprost Injectable Product 1156290
    • Iloprost Injection [Aurlumyn] 2680308
    • Aurlumyn Injectable Product 2680307
    • Injection 1649574
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Iloprost 0.1 MG/ML [Aurlumyn] SBDC · 2680306
  • Iloprost Injection [Aurlumyn] SBDF · 2680308
  • Aurlumyn Injectable Product SBDG · 2680307
  • Aurlumyn BN · 2680305

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2680309 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50633-0340-01 1 VIAL, SINGLE-DOSE in 1 CARTON (50633-340-01) / 1 mL in 1... AURLUMYN BTG International Inc 2026-03-01
Observed labelers: BTG International Inc (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.